197 related articles for article (PubMed ID: 22901944)
1. Virus safety of plasma products using 20 nm instead of 15 nm filtration as virus removing step.
Koenderman AH; ter Hart HG; Prins-de Nijs IM; Bloem J; Stoffers S; Kempers A; Derksen GJ; Al B; Dekker L; Over J
Biologicals; 2012 Nov; 40(6):473-81. PubMed ID: 22901944
[TBL] [Abstract][Full Text] [Related]
2. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
4. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
5. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
6. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
7. Viral safety of C1-inhibitor NF.
Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
[TBL] [Abstract][Full Text] [Related]
8. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
9. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
10. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
11. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
12. Nanoceramics for blood-borne virus removal.
Zhao Y; Sugiyama S; Miller T; Miao X
Expert Rev Med Devices; 2008 May; 5(3):395-405. PubMed ID: 18452389
[TBL] [Abstract][Full Text] [Related]
13. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
14. Different behavior of erythrovirus B19 and torquetenovirus in response to a single step of albumin purification.
Azzi A; Maggi F; Zakrzewska K; Menconi MC; Di Pietro N; Salotti V; Farina C; Andreoli E; Fiorentino B; Angelini C; Corcioli F; Bendinelli M
Transfusion; 2006 Jul; 46(7):1162-7. PubMed ID: 16836563
[TBL] [Abstract][Full Text] [Related]
15. Effective poxvirus removal by sterile filtration during manufacture of plasma derivatives.
Berting A; Goerner W; Spruth M; Kistner O; Kreil TR
J Med Virol; 2005 Apr; 75(4):603-7. PubMed ID: 15714487
[TBL] [Abstract][Full Text] [Related]
16. Pathogen safety of Beriate®.
Gröner A
Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
[TBL] [Abstract][Full Text] [Related]
17. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
Omar A; Kempf C
Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
[TBL] [Abstract][Full Text] [Related]
18. Integration of Planova filters in manufacturing processes of biologicals improve the virus safety effectively: A review of publicly available data.
Gröner A
Biotechnol Prog; 2024; 40(1):e3398. PubMed ID: 37985214
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
20. Impact of virus preparation quality on parvovirus filter performance.
Slocum A; Burnham M; Genest P; Venkiteshwaran A; Chen D; Hughes J
Biotechnol Bioeng; 2013 Jan; 110(1):229-39. PubMed ID: 22766979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
